Host: |
Rabbit |
Applications: |
WB/ELISA |
Reactivity: |
Human/Mouse |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Clonality: |
Polyclonal |
Conjugation: |
Unconjugated |
Isotype: |
IgG |
Formulation: |
PBS with 0.01% Thimerosal, 50% Glycerol, pH 7.3. |
Purification: |
Affinity purification |
Concentration: |
Lot specific |
Dilution Range: |
WB:1:500-1:2000ELISA:Recommended starting concentration is 1 Mu g/mL. Please optimize the concentration based on your specific assay requirements. |
Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
Gene Symbol: |
ESS2 |
Gene ID: |
8220 |
Uniprot ID: |
ESS2_HUMAN |
Immunogen Region: |
1-300 |
Specificity: |
Recombinant fusion protein containing a sequence corresponding to amino acids 1-300 of human DGCR14 (NP_073210.1). |
Immunogen Sequence: |
METPGASASSLLLPAASRPP RKREAGEAGAATSKQRVLDE EEYIEGLQTVIQRDFFPDVE KLQAQKEYLEAEENGDLERM RQIAIKFGSALGKMSREPPP PYVTPATFETPEVHAGTGVV GNKPRPRGRGLEDGEAGEEE EKEPLPSLDVFLSRYTSEDN ASFQEIMEVAKERSRARHAW LYQAEEEFEKRQKDNLELPS AEHQAIESSQASVETWKYKA KNSLMYYPEGVPDEEQLFK |
Tissue Specificity | Highly expressed in heart, brain and skeletal muscle. Detected at low levels in placenta. |
Function | May be involved in pre-mRNA splicing. |
Protein Name | Splicing Factor Ess-2 HomologDigeorge Syndrome Critical Region 13Digeorge Syndrome Critical Region 14Digeorge Syndrome Protein HDgs-HProtein Es2 |
Cellular Localisation | Nucleus |
Alternative Antibody Names | Anti-Splicing Factor Ess-2 Homolog antibodyAnti-Digeorge Syndrome Critical Region 13 antibodyAnti-Digeorge Syndrome Critical Region 14 antibodyAnti-Digeorge Syndrome Protein H antibodyAnti-Dgs-H antibodyAnti-Protein Es2 antibodyAnti-ESS2 antibodyAnti-DGCR13 antibodyAnti-DGCR14 antibodyAnti-DGSH antibodyAnti-DGSI antibodyAnti-ES2 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance